BioHarvest Sciences produces active plant ingredients without growing the plant itself
Last updated: 08:42 12 Nov 2026 EST, First published: 11:00 26 Nov 2021 EST
Snapshot
- BioHarvest Sciences posts US$7.9M Q3 revenue as fragrance supply deal sets up 2027 growth
- BioHarvest Sciences Partners with Tate & Lyle to Develop Sustainable Plant-Based Sweeteners
About the company
BioHarvest is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant.
The company is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements.
How it is doing
BioHarvest Sciences Inc (NASDAQ:BHST) reported third-quarter revenue of US$7.9 million and said its first manufacturing and supply agreement, covering 20 tons of a rare plant-based fragrance ingredient, is estimated to generate US$20 million to US$30 million in revenue in 2027 and 2028.
The exclusive agreement extends an existing multi-stage development program with a UAE-based customer. The company said limited production could begin as early as the first quarter of 2027.
Stage 1 development was completed in March 2026, and Stage 2 is expected to finish within six to nine months.
The agreement marks a significant step towards commercializing BioHarvest's CDMO capabilities, as the company shifts resources towards a smaller number of development programs with a clearer path to manufacturing.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Tuesday that Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing, the second product from its Botanical Synthesis technology to reach that stage.
The company said Olive Cell has completed large-scale bioreactor scale-up, manufacturing readiness and a self-affirmed U.S. Generally Recognized as Safe (GRAS) process.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday its Botanical Synthesis platform can produce the next-generation sweetener targeted in its joint development program with Tate & Lyle.
Tate & Lyle, a supplier of ingredient solutions for food and beverages, is looking to broaden its range of sweeteners as manufacturers seek ways to cut sugar and calories without losing taste and functionality, the companies said.
What management says
BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share that the company has announced a strategic collaboration with Tate & Lyle PLC (LSE:TATE), a global leader in ingredient solutions for healthier food and beverages. This partnership aims to create next-generation, plant-based molecules that address the growing consumer demand for affordable, nutritious, and sustainable food and beverage ingredients.
The collaboration will focus on developing botanical sweetening ingredients using plant-derived molecules through BioHarvest’s proprietary platform. These innovative sweeteners will deliver a sugar-like taste without any aftertaste, providing consumers with healthier ingredient options. The solutions promise to be more cost-effective for the food and beverage industry while significantly reducing the land and water use typically required for traditional extraction methods.